More new good news for research into myelodysplastic syndromes at the institute
The TRANSCAN-2 European Network has awarded the research grant Euro MDS to an international consortium for Translational research on rare cancers, the Myelodysplastic syndromes research group led by Dr Francesc Solé is one of the partners.
The project entitled: An integrated European platform to conduct translational studies in myelodysplastic syndromes (MDS) based on the EuroBloodNet infrastructure, is coordinated from the IRCCS Humanitas Research Hospital & Humanitas University in Milan, Italy. As well as the IJC, the Hospital Saint Louis in Paris, France and the Technical University of Dresden, Germany are partners.
MDS cases vary greatly in the biology behind the disease. It is fundamental for research to collect large numbers of samples from patients from different countries in order to see sufficient examples of different forms. In this project, with European funding, the international team will be looking at genetic and clinical information in patients and mapping their progress. The aim is to identify specific changes that we can confidently use to evaluate the risk of a certain individual developing the disease and how they will respond to different treatments. Ironically we must study large groups of patients in order to be able treat individuals in a tailored and personalized way in the future, explains Dr Solé.
The Euro MDS Translational research on rare cancers project will be funded through the TRANSCAN-2 Joint Transnational Call 2017 (JTC 2017). The ERA-NET: Aligning national/regional translational cancer research programmes and activities - TRANSCAN-2 is a five-year project (2015-2019) funded by the European Commission under the EU framework programme Horizon2020 (Grant Agreement no. 643638). It is the continuation of the previous ERA-NET on translational cancer research TRANSCAN, funded under the FP7 from 2011 to 2014.
TRANSCAN-2 is a collaborative network of ministries, funding agencies and research councils with programmes in translational cancer research. The network is composed of 28 partners from 19 Countries. In Spain the funding is managed by the Spanish Association Against Cancer Scientific Foundation (AECC).